Times Square Capital Management, LLC Taysha Gene Therapies, Inc. Transaction History

Times Square Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	SELL	$2.47 - $6.77 $1.64 Million - $4.51 Million	-665,900 Closed	0 $0
Q1 2022 May 06, 2022	BUY	$5.22 - $11.86 $35,496 - $80,648	6,800 Added 1.03%	665,900 $4.34 Million
Q4 2021 Feb 04, 2022	BUY	$11.43 - $19.2 $97,155 - $163,200	8,500 Added 1.31%	659,100 $7.68 Million
Q3 2021 Nov 08, 2021	SELL	$15.82 - $21.57 $518,896 - $707,496	-32,800 Reduced 4.8%	650,600 $12.1 Million
Q2 2021 Aug 09, 2021	BUY	$19.29 - $26.38 $5.52 Million - $7.55 Million	286,200 Added 72.05%	683,400 $14.5 Million
Q1 2021 May 12, 2021	SELL	$20.3 - $31.75 $552,160 - $863,600	-27,200 Reduced 6.41%	397,200 $8.06 Million
Q4 2020 Feb 12, 2021	BUY	$19.14 - $28.13 $128,238 - $188,471	6,700 Added 1.6%	424,400 $11.3 Million
Q3 2020 Nov 06, 2020	BUY	$22.4 - $24.47 $9.36 Million - $10.2 Million	417,700 New	417,700 $9.36 Million

119

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $97.2M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Times Square Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Times Square Capital Management, LLC with notifications on news.